Clinical trials: Aphasia, Primary Progressive
Dementia, Frontotemporal
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VES001 in Healthy Participants
This is a Phase 1, randomized, placebo-controlled, double-blind study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of VES001 in a two part followed by a…
- Trial name
- SORT-IN-1 (NCT06226064)
- Testing
- VES001
- Where
- Netherlands
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Vesper Biotechnologies ApS
GM2 Gangliosidosis, Niemann-Pick Type C Disease
A Study to Evaluate the Safety and Efficacy of Nizubaglustat (AZ-3102) in Patients With GM2 Gangliosidosis or Niemann-Pick Type C Disease
This open-label study aims to gather long-term safety, tolerability, PK, biomarker, and clinical efficacy data relating to daily administration of Nizubaglustat in participants previously enrolled in the Phase 2 RAINBOW study…
- Trial name
- PRISMA (NCT07399704)
- Testing
- AZ-3102
- Where
- 3 sites in Brazil
- Volunteers
- 21 people
- Sponsor
- Azafaros B.V.
Rare Disorders, Undiagnosed Disorders
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research.
- Conditions
- Rare Disorders, Undiagnosed Disorders, Disorders of Unknown Prevalence, Cornelia De Lange Syndrome
- Trial name
- CoRDS (NCT01793168)
- Where
- United States
- Volunteers
- 20,000 people
- Sponsor
- Sanford Health
Primary Progressive Aphasia
Preventing Language Decline in Dementia
This study will establish factors fundamental to the improvement in communication and quality of life for people with dementia known as primary progressive aphasia (PPA).
- Trial name
- NCT02541097
- Testing
- Language therapy
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Baycrest
Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD)
Alzheimer's Disease Neuroimaging Initiative 3
Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging Initiative (ADNI) has been realized in informing the design of therapeutic trials in AD.
- Trial name
- ADNI3 (NCT02854033)
- Where
- 59 sites in United States, Canada
- Volunteers
- 1,141 people, healthy volunteers welcome
- Sponsor
- University of Southern California
Primary Tauopathies, Corticobasal Degeneration Syndrome
BIIB092 in Primary Tauopathies: CBS, nfvPPA, sMAPT, and TES
A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Parallel Cohort Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of Intravenously Infused BIIB092 in Patients with Four Different…
- Conditions
- Primary Tauopathies, Corticobasal Degeneration Syndrome, Frontotemporal Lobar Degeneration With Tau Inclusions, MAPT Mutation Carriers, Symptomatic
- Trial name
- TauBasket (NCT03658135)
- Testing
- BIIB092
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of California, San Francisco
Behavioral Variant Frontotemporal Dementia (bvFTD)
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
The purpose of this study is to demonstrate the safety and efficacy of TRx0237 in the treatment of patients with behavioral variant frontotemporal dementia (bvFTD).
- Trial name
- NCT01626378
- Testing
- TRx0237
- Where
- 67 sites in United States, Australia and 10 more
- Volunteers
- 220 people
- Sponsor
- TauRx Therapeutics Ltd
Alzheimer Disease
Retinal Nerve Fiber Layer Thickness and Cerebrospinal Fluid Aβ/Tau
To test the hypothesis that retinal nerve fiber layer (RNFL) thickness is correlated with Aβ and Tau concentration of cerebrospinal fluid (CSF) in an older population.
- Trial name
- NCT03447613
- Testing
- surgery
- Where
- China
- Volunteers
- 86 people
- Sponsor
- Shanghai 10th People's Hospital
Frontotemporal Lobar Degeneration
The Skin as a Window to the Central Nervous System in Frontotempolar Lombar Degeneration
Frontotemporal lobar degeneration (FTLD) is a clinically heterogeneous syndrome, characterized by progressive decline in behaviour and/or language.
- Trial name
- PROTEINOSKIN (NCT06490822)
- Testing
- Skin biopsy
- Where
- France
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Nantes University Hospital
Primary Progressive Aphasia
Stimulating the Aging Brain Using Brain and Sensory Stimulation
The goal of this project is to investigate whether transcranial electrical stimulation and sensory stimulation affect language outcomes in individuals with primary progressive aphasia (PPA).
- Trial name
- StAB (NCT07650188)
- Testing
- tACS or multisensory stimulation
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Medical College of Wisconsin
Alzheimer's Disease (AD), Neurodegenerative Disease
A Biomarker-chip Assay in Preserved Red Blood Cells for the Diagnosis of Alzheimer's Disease
The ADCHIP study (ST0067) is a non-interventional, monocentric, prospective study conducted by Amoneta Diagnostics and the Leenaards Memory Center (Lausanne, Switzerland).
- Conditions
- Alzheimer's Disease (AD), Neurodegenerative Disease, Dementia, Frontotemporal Dementia (FTD)
- Trial name
- ADCHIP (NCT07307872)
- Where
- Switzerland
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Amoneta Diagnostics SAS
Alzheimer Disease, Dementia With Lewy Bodies (DLB)
Retrospective Observational Study of Blood-based Biomarkers in the Diagnosis and Monitoring of Patients With a Neurodegenerative Disease or Mental Disorder
This is a retrospective observational study to evaluate the clinical utility of blood-based biomarkers in the diagnosis and management of patients with a neurodegenerative disease (ND) or mental disorder (MD).
- Conditions
- Alzheimer Disease, Dementia With Lewy Bodies (DLB), Frontotemporal Dementia (FTD), Major Depressive Disorder (MDD)
- Trial name
- Synapsing-BK (NCT07314190)
- Where
- Spain
- Volunteers
- 1,799 people, healthy volunteers welcome
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Frontotemporal Lobar Degeneration
Natural History Characterization in Symptomatic and Asymptomatic Progranuline Gene Mutation Carriers
The purpose of this study is to investigate whether cognitive deficits, structural and functional changes can be detected before symptom onset in presymptomatic progranuline mutation carriers.
- Trial name
- Predict-PGRN (NCT04014673)
- Testing
- Behavioral : Characterization
- Where
- 2 sites in France
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Frontotemporal Lobar Degeneration, Dementia
PET Evaluation of Brain Peripheral Benzodiazepine Receptors Using [11C]PBR28 in Frontotemporal Dementia
This study will use positron emission tomography (PET) imaging to measure a receptor in the brain that is involved in inflammation.
- Trial name
- NCT00613119
- Where
- United States
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Alzheimer Disease
COGNIShunt® System for Alzheimer's Disease
This is a study of the effect on the progression of Alzheimer's Disease of a surgically implanted shunt (tube) to increase the flow of cerebrospinal fluid and improve the clearance of potential neurotoxins from the fluid bathing…
- Trial name
- NCT00056628
- Testing
- The COGNIShunt® System
- Volunteers
- 250 people
- Sponsor
- Eunoe
Alzheimer Disease, Dementia
Educational Support Group Program for Bilingual and Spanish-speaking Carepartners and People With Progressive Aphasia
The current study aims to examine the benefits of an education/support group program for individuals with progressive aphasia (caused by various etiologies, diagnoses) and their carepartners.
- Conditions
- Alzheimer Disease, Dementia, Primary Progressive Aphasia, Aphasia
- Trial name
- NCT06511752
- Testing
- Psychosocial educational, support group and implementation of strategies
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University of Texas at Austin
Sphingomyelin Lipidosis
Compassionate Use Program for Olipudase Alfa Enzyme Replacement Therapy for Patients With Chronic Acid Sphingomyelinase Deficiency (ASMD)
The objective of this program is to provide access to enzyme replacement therapy (ERT) with olipudase alfa for certain patients with ASMD, a severe, life threatening disease, that could not participate in the olipudase clinical…
- Trial name
- NCT04877132
- Testing
- olipudase alfa (GZ402665)
- Sponsor
- Sanofi
Primary Progressive Aphasia
The Effects of a Multimodal Approach for the Treatment of PPA
Primary Progressive Aphasia (PPA) is an untreatable neurodegenerative disorder that disrupts language functions. Available therapies are mainly symptomatic and recently attention has been gained by new techniques that allow for…
- Trial name
- ACROSS (NCT04187391)
- Testing
- Active tDCS, Language training, Unstructured cognitive training
- Where
- Italy
- Volunteers
- 47 people
- Sponsor
- IRCCS Centro San Giovanni di Dio Fatebenefratelli
Primary Progressive Aphasia, Neurodegenerative Diseases
Home-Based Exercise in Primary Progressive Aphasia (HEPPA)
This pilot study aims to evaluate the feasibility of a novel home-based multicomponent exercise program in adults clinically diagnosed with Primary Progressive Aphasia
- Conditions
- Primary Progressive Aphasia, Neurodegenerative Diseases, Logopenic Progressive Aphasia, Semantic Dementia
- Trial name
- HEPPA (NCT06181500)
- Testing
- Home-based multicomponent exercise intervention program
- Where
- 2 sites in Canada
- Volunteers
- 13 people
- Sponsor
- Montreal Heart Institute
Parkinson Disease, Parkinsonism
More Than a Movement Disorder: Applying Palliative Care to Parkinson's Disease
This is a two-center (University of Colorado, University of California San Francisco) community-based comparative effectiveness study of outpatient palliative care for Parkinson's disease (PD) and related disorders (progressive…
- Conditions
- Parkinson Disease, Parkinsonism, Lewy Body Disease, Supranuclear Palsy, Progressive
- Trial name
- MTMD (NCT03076671)
- Testing
- Palliative Care
- Where
- 2 sites in United States
- Volunteers
- 783 people
- Sponsor
- University of Colorado, Denver